A Phase 1b Study of Imvotamab in Severe Systemic Lupus Erythematosus
This research study is about a new medicine called Imvotamab for people who have a serious autoimmune disease called Systemic Lupus Erythematosus (often just called lupus). Lupus can cause the immune system to mistakenly attack healthy parts of the body, leading to problems in joints, skin, kidneys, and other organs. This is an early-stage study, meaning it’s one of the first times this medicine is being tested in people. Doctors want to see if Imvotamab is safe to use and how it affects the body. It's not about whether it cures lupus yet, but about understanding the medicine better. Anyone aged 18 or over with severe lupus could potentially be eligible to join.
En un coup d'œil
De quoi parle cette étude ?
This research study is exploring a new medicine called Imvotamab for people living with severe Systemic Lupus Erythematosus, a condition commonly known as lupus. Lupus is a long-term illness where your body's immune system, which normally fights off infections, starts attacking your own healthy tissues and organs. This can cause a range of problems, from joint pain and tiredness to more serious issues affecting the kidneys, heart, or brain. When lupus is severe, it means these symptoms are particularly serious and challenging to manage.
Because lupus is a complex condition for which there isn't yet a cure, scientists are always looking for new and better ways to manage its symptoms and improve quality of life. This particular study is in an early stage of development. This means that researchers are primarily focused on understanding if the medicine, Imvotamab, is safe for people to take and how it behaves in the body. They want to find out the right dose and see if there are any side effects.
It's important to remember that this study is not designed to prove that Imvotamab will cure lupus or treat all symptoms at this stage. Instead, the information gathered from this early research will help doctors decide if it's worth exploring this medicine further in bigger studies to see if it can effectively treat lupus in the future. Participating in such a study contributes to medical knowledge that could benefit many people with lupus down the line.
Points clés
- This study is testing a new medicine called Imvotamab for severe lupus.
- It's an early-stage study focused on safety and how the medicine works.
- You must be 18 years or older with severe lupus to be considered.
- Participation involves regular clinic visits, tests, and receiving the study medicine.
- There are potential benefits (new treatment, close monitoring) and risks (unknown side effects).
- Vous pouvez vous retirer de l'étude à tout moment.
Qui peut être éligible ?
To be considered for this study, you would need to be an adult, 18 years old or older. The study is open to both men and women.
The most important requirement is that you have a diagnosis of severe Systemic Lupus Erythematosus. This means your lupus is causing significant problems and your doctor views it as a serious case. Beyond these basic points, there will be other specific health checks and tests to make sure that taking part in the study is safe and appropriate for you.
These checks might include reviewing your medical history, current health, and any other medications you are taking. The study team will explain all the requirements in detail.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Do you have a diagnosis of severe Systemic Lupus Erythematosus (lupus)?
- Are you able to attend regular appointments for the study?
- Are you willing to consider taking an experimental medicine?
En quoi consiste la participation ?
If you decide to take part in this study, you will work closely with a team of doctors and nurses. The specific details of what you'll need to do, such as how many visits you'll have, how often, and how long the study will last, would be fully explained by the study team. Generally, early-stage studies like this often involve a number of visits to the clinic for health checks, blood tests, and to receive the study medicine, Imvotamab.
You would receive the study medicine as instructed by the team. There will be regular assessments, which might include giving blood samples, having physical examinations, and answering questions about how you are feeling. This helps the doctors monitor your health and how the medicine is affecting you. After the main treatment period, there will usually be a follow-up period to continue checking on your health and any long-term effects. The total duration of your involvement could range from several months to even longer, depending on the study design.
Risques et avantages potentiels
Emplacements (1)
- —Non vérifiéPologne
Questions fréquentes
What is Systemic Lupus Erythematosus (lupus)?
Lupus is a long-term condition where your body's immune system mistakenly attacks healthy tissues, causing inflammation and damage in various parts of the body like joints, skin, and organs.
What does 'Phase 1b Study' mean?
This is an early stage of research where doctors are mainly checking if a new medicine is safe for people and how it works in the body. It’s not about curing the disease yet.
What is Imvotamab?
Imvotamab is the name of the new medicine being tested in this study for severe lupus. It's an experimental treatment, meaning it's not approved for general use yet.
Dois-je payer pour participer à l'étude ?
No, you should not have to pay to take part in a clinical trial. The study usually covers the costs of the experimental medicine and study-related visits and tests.
Que se passe-t-il si je change d'avis après avoir rejoint ?
You are free to leave the study at any time, for any reason, and it will not affect your regular medical care. Your decision will be respected.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.